| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1.
|
Blood
|
1998
|
2.78
|
|
2
|
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.
|
Blood
|
2000
|
2.00
|
|
3
|
Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47.
|
Blood
|
1999
|
1.77
|
|
4
|
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
|
Blood
|
1999
|
1.52
|
|
5
|
Surface phenotype analysis of human monocyte to macrophage maturation.
|
J Leukoc Biol
|
1990
|
1.52
|
|
6
|
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
|
Cancer Res
|
2001
|
1.50
|
|
7
|
Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells.
|
Blood
|
2001
|
1.44
|
|
8
|
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
|
Leukemia
|
2012
|
1.33
|
|
9
|
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.
|
Ann Oncol
|
2011
|
1.24
|
|
10
|
Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.
|
Cancer Res
|
1990
|
1.23
|
|
11
|
Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow.
|
Blood
|
1995
|
1.19
|
|
12
|
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia.
|
Br J Haematol
|
2000
|
1.19
|
|
13
|
Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor.
|
Blood
|
1998
|
1.14
|
|
14
|
The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors.
|
Blood
|
1999
|
1.08
|
|
15
|
Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma.
|
Eur J Cancer
|
1999
|
1.06
|
|
16
|
Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.
|
Cancer Res
|
2000
|
0.98
|
|
17
|
Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
|
Cancer Res
|
1998
|
0.98
|
|
18
|
Human macrophages can express the Hodgkin's cell-associated antigen Ki-1 (CD30).
|
Am J Pathol
|
1989
|
0.97
|
|
19
|
Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters.
|
Proc Natl Acad Sci U S A
|
1999
|
0.91
|
|
20
|
PCV salvage chemotherapy for recurrent primary CNS lymphoma.
|
Neurology
|
2000
|
0.91
|
|
21
|
Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia.
|
Br J Haematol
|
2000
|
0.91
|
|
22
|
Infection of monocytes/macrophages by HIV in vitro.
|
Res Virol
|
1990
|
0.90
|
|
23
|
Regulation of transendothelial migration of hematopoietic progenitor cells.
|
Ann N Y Acad Sci
|
1999
|
0.90
|
|
24
|
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.
|
Crit Rev Oncol Hematol
|
2007
|
0.89
|
|
25
|
How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation? Results of a computer simulation.
|
Exp Hematol
|
1999
|
0.87
|
|
26
|
AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors.
|
Blood
|
1999
|
0.86
|
|
27
|
Maintenance of transplantation potential in ex vivo expanded CD34(+)-selected human peripheral blood progenitor cells.
|
Blood
|
1994
|
0.85
|
|
28
|
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.
|
Blood
|
1999
|
0.84
|
|
29
|
Increased incidence of IgA antibodies to the Epstein-Barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia.
|
Int J Cancer
|
1986
|
0.84
|
|
30
|
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
|
Br J Cancer
|
2011
|
0.83
|
|
31
|
Dendritic cells in cancer vaccines.
|
Exp Hematol
|
2001
|
0.83
|
|
32
|
Microculture assay for human macrophage maturation in vitro. Cell-ELISA analysis of differentiation antigen expression.
|
Int Arch Allergy Appl Immunol
|
1988
|
0.83
|
|
33
|
Enzyme-linked immunosorbent assay for IgG antibodies to Epstein-Barr virus-associated early antigens and viral capsid antigen.
|
J Immunol Methods
|
1984
|
0.83
|
|
34
|
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
|
Ann Hematol
|
2000
|
0.83
|
|
35
|
Defective monocyte-to-macrophage maturation in patients with aplastic anemia.
|
Blood
|
1989
|
0.82
|
|
36
|
Expression of novel surface antigens on early hematopoietic cells.
|
Ann N Y Acad Sci
|
1999
|
0.82
|
|
37
|
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
|
Ann Oncol
|
1997
|
0.82
|
|
38
|
A new approach to adoptive immunotherapy of cancer using tumorcytotoxic macrophages grown from peripheral blood monocytes.
|
Cancer Detect Prev
|
1991
|
0.82
|
|
39
|
Defective monocyte to macrophage maturation in human immunodeficiency virus infection.
|
Res Virol
|
1990
|
0.81
|
|
40
|
Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34(+) cells with stem cell factor and promegapoietin.
|
Exp Hematol
|
2000
|
0.80
|
|
41
|
Activation of human monocyte-derived macrophages cultured on Teflon: response to interferon-gamma during terminal maturation in vitro.
|
Immunobiology
|
1988
|
0.79
|
|
42
|
Peripheral blood stem cells: in vivo biology and therapeutic potential.
|
Stem Cells
|
1994
|
0.79
|
|
43
|
Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma.
|
Anticancer Drugs
|
1999
|
0.79
|
|
44
|
High-dose chemotherapy with autologous peripheral blood stem cell transplantation for metastatic gastric leiomyosarcoma.
|
Bone Marrow Transplant
|
1997
|
0.79
|
|
45
|
Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.
|
Br J Haematol
|
1999
|
0.78
|
|
46
|
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
|
Blood
|
2001
|
0.78
|
|
47
|
2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
|
Blood
|
1998
|
0.78
|
|
48
|
Developmental regulation of myeloid gene expression and demethylation during ex vivo culture of peripheral blood progenitor cells.
|
Blood
|
1996
|
0.78
|
|
49
|
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
|
Ann Oncol
|
1999
|
0.78
|
|
50
|
Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
|
Bone Marrow Transplant
|
1996
|
0.78
|
|
51
|
In vivo biology and therapeutic potential of hematopoietic growth factors and circulating progenitor cells.
|
Semin Oncol
|
1992
|
0.77
|
|
52
|
Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34(+) cells.
|
Exp Hematol
|
2000
|
0.77
|
|
53
|
A new look at the role of p53 in leukemia cell sensitivity to chemotherapy.
|
Leukemia
|
1997
|
0.77
|
|
54
|
Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells.
|
Blood
|
1996
|
0.77
|
|
55
|
Interleukin-3 and granulocyte-macrophage colony-stimulating factor in combination: clinical implication.
|
Med Pediatr Oncol Suppl
|
1992
|
0.76
|
|
56
|
Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC).
|
Stem Cells
|
2000
|
0.76
|
|
57
|
Characterization of purified and ex vivo manipulated human hematopoietic progenitor and stem cells in xenograft recipients.
|
Ann N Y Acad Sci
|
1999
|
0.76
|
|
58
|
Expression of laminin beta2 chain in normal human bone marrow.
|
Blood
|
1999
|
0.76
|
|
59
|
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report.
|
Ann Oncol
|
1999
|
0.75
|
|
60
|
The role of cytokines in oncology.
|
Int J Cell Cloning
|
1991
|
0.75
|
|
61
|
Peripheral blood progenitor cell transplantation: where do we stand? Chairman's Summary of the European School of Oncology Task Force meeting Peripheral Blood progenitor cell's held September 29-30, 1995.
|
Ann Oncol
|
1996
|
0.75
|
|
62
|
Ex vivo expansion of hematopoietic progenitor cells for clinical use.
|
Semin Hematol
|
1998
|
0.75
|
|
63
|
[Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients].
|
Dtsch Med Wochenschr
|
1984
|
0.75
|
|
64
|
[Immunoscintigraphy of bone marrow in plasmacytoma].
|
Nuklearmedizin
|
1995
|
0.75
|
|
65
|
Haematopoietic growth factors in clinical medicine.
|
Eur J Cancer
|
1994
|
0.75
|
|
66
|
Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification.
|
Eur J Cancer
|
1993
|
0.75
|
|
67
|
Combination of cytokines: current status and future prospects.
|
Br J Haematol
|
1991
|
0.75
|
|
68
|
Ex vivo manipulation of hematopoietic stem and progenitor cells.
|
Stem Cells
|
1998
|
0.75
|
|
69
|
The fascinating life of hematopoietic stem cells.
|
Nat Med
|
1998
|
0.75
|
|
70
|
Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients.
|
Br J Haematol
|
1998
|
0.75
|
|
71
|
Retraction: reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo.
|
N Engl J Med
|
2001
|
0.75
|
|
72
|
Neo-adjuvant high-dose chemotherapy with autologous peripheral blood stem cell transplantation for inoperable relapse of nuchal liposarcoma resistant to standard-dose chemotherapy.
|
Ann Oncol
|
1996
|
0.75
|
|
73
|
Detection of IgA antibodies to Epstein-Barr virus-associated antigens by ELISA.
|
J Immunol Methods
|
1984
|
0.75
|
|
74
|
Clinical use for expanded peripheral blood stem cells.
|
Baillieres Best Pract Res Clin Haematol
|
2000
|
0.75
|
|
75
|
The clinical role of hematopoietic growth factors in peripheral blood progenitor cell transplantation.
|
Vox Sang
|
1994
|
0.75
|
|
76
|
Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients.
|
Eur J Immunol
|
1996
|
0.75
|
|
77
|
Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients.
|
J Clin Oncol
|
2002
|
0.75
|
|
78
|
The use of hematopoietic growth factors for high-dose chemotherapy and peripheral blood progenitor cell transplantation.
|
Semin Oncol
|
1994
|
0.75
|
|
79
|
Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment.
|
Cancer
|
2001
|
0.75
|
|
80
|
Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
|
J Hematother Stem Cell Res
|
2001
|
0.75
|
|
81
|
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
|
Ann Oncol
|
1997
|
0.75
|
|
82
|
CT and MR features of primary pulmonary hemangiopericytomas.
|
J Comput Assist Tomogr
|
1993
|
0.75
|